How profitable is Intelligent Bio Solutions Inc. (INBS)?

In FY 2025 (10-K), INBS converted $3.1M of revenue into a 40.8% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Stock Ratings / Health Care / INBS / financials

TNON (30) SNOA (34) NVNO (33) WOK (51) ⌘ Pro Terminal →

Intelligent Bio Solutions Inc. (INBS) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.66 -5.68% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.64

Intelligent Bio Solutions Inc. (INBS) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $5.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on INBS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is INBS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Intelligent Bio Solutions Inc. (NASDAQ: INBS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $1.66 (-5.68% 1D, market cap $5.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, INBS ranks #893 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does INBS compare to TNON and SNOA in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), INBS carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 40.8%, and ROIC of -35.0%. By comparison, TNON (Tenon Medical Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $5.5M) and SNOA (Sonoma Pharmaceuticals Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M). Among the 5-stock peer group, INBS leads on earnings multiple (N/A) while INBS leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for INBS?

▼

Per INBS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001725430), Intelligent Bio Solutions Inc. generated $3.1M in revenue (-1.9% YoY), -$10.6M in net income, and -$9.9M in free cash flow against $17.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.64 (-1.21%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-13.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INBS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (27/100 Composite)

🔍 WHY INBS SCORES 27/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+7/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 40.8% Gross Margin

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (26% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 52.5 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$1.48+12.8% Next Q

Q2 (-2Q)

Grade E$1.67+3% Next Q

Q3 (-1Q)

Grade E$1.72-3.5% Next Q

Current

Grade E$1.66-10.3% Hist 90D α

Trajectory: E (19) → E (27)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a INBS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While INBS currently carries a cautious 27/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.85) and Max Pain ($1.74) forces dealer call-delta covering toward $26.14.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INBS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “INBS Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”

YES 27%NO 73%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How INBS Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $1.3M

FY24

Rev $3.1M

FY25

Rev $3.1M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$3.1M	40.8%	-80%	-$10.6M	-$9.9M	-45%
FY 2024	$3.1M	45.8%	-80%	-$10.2M	-$9.8M	-45%
FY 2023	$1.3M	40.8%	-80%	-$10.6M	-$7.4M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INBS)

✓Walkthrough of INBS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

INBS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -33.60%⚡ TESTING RESISTANCE

2026-11-03O $1.83H $1.83L $1.66C $1.66VOL 18.2K

RES: $1.83SUP: $1.02SMA50: $1.85SMA200: $3.05

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INBS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INBS Butterfly Map → + Track INBS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -1.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on INBS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INBS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for INBS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INBS)

Health Care Rank #893 of 1016 ⚔️ TNON vs INBS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INBS vs. TNON, SNOA, NVNO, WOK)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Intelligent Bio Solutions Inc. (INBS) ranks #893 by composite RQD confidence (27/100, grade E) and #929 by equity capitalization ($5.8M). Within this direct 5-issuer industry benchmark cohort, INBS leads on earnings valuation at N/A trailing P/E, while INBS leads on capital efficiency and profitability with -35.0% ROIC and 40.8% gross margin. WOK currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with INBS at 27/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
INBS ACTIVE Intelligent Bio Solutions Inc.	E	27/100	—	40.8%	-35.0%	-5.68%	$5.8M	Benchmark Subject
TNON Tenon Medical Inc.	E	30/100	—	59.8%	-35.0%	-5.85%	$5.5M	/tnon-vs-inbs →
SNOA Sonoma Pharmaceuticals Inc.	E	34/100	—	38.0%	-35.0%	0.00%	$5.3M	/snoa-vs-inbs →
NVNO enVVeno Medical Corporation	E	33/100	—	—	-35.0%	+2.08%	$4.7M	/nvno-vs-inbs →
WOK WORK Medical Technology Group LTD (Class A)	D	51/100	—	—	—	0.00%	$4.5M	/wok-vs-inbs →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001725430

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Intelligent Bio Solutions Inc. (INBS) reported GAAP revenue of $3.1M (-1.9% vs. FY2024 revenue of $3.1M , and +142.9% cumulative change since FY2023) , GAAP net income of -$10.6M, operating cash flow of -$9.7M, and free cash flow of -$9.9M (-1.2% YoY). On the balance sheet, INBS closed FY2025 with $17.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$3.1M	-$10.6M	-$9.7M	-$9.9M	$17.7M	—
FY2024 (FY)	2024-06-30	$3.1M	-$10.2M	-$9.6M	-$9.8M	$8.7M	—
FY2023 (FY)	2023-06-30	$1.3M	-$10.6M	-$7.4M	-$7.4M	—	—

3. INBS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INBS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does INBS compare to TNON and SNOA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for INBS?

Where is INBS trading relative to its 50-day, 200-day, and 52-week technical levels?

INBS last traded at $1.66 (-5.68% on volume of 26,489 shares), positioning the stock -10.27% below its 50-day simple moving average ($1.85) and -45.57% below its 200-day simple moving average ($3.05). Across its 52-week range of $1.35 to $24.90, INBS sits at the 1.3% percentile with a 14-day RSI of 52.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.45 to $1.87).

Direct Sub-Reports: INBS RQD Cockpit INBS 12M Forecast INBS Earnings & Move INBS Dividends & DRIP INBS Insiders & 13F INBS Whale Options INBS Profit Sankey INBS News & Why

ROARABLE RATING BRIEF • RQD 27/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

INBS — Intelligent Bio Solutions Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:52:47Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

INBS scores 29 out of 100 and receives a letter grade of E, with the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." The score is built from five pillars, each weighted at 20 points:

Fundamental Cash Engine (7 / 20): Cited alongside ROIC of -35% and an FCF yield of 0%. The score reflects that the business is not currently generating returns on invested capital or free cash flow relative to its market value.
Whale / 13F Flow (7 / 20): Reflects institutional accumulation and options positioning. The holders section contains no institutional data in the source, so this pillar cannot be traced to specific filings here.
Insider Conviction (3 / 20): Reflects SEC Form 4 and Congressional PTR cluster flow. This is the lowest-scoring pillar and indicates weak insider-side signaling in the source data.
Macro Regime Fit (7 / 20): Reflects a beta of 1.0 and sector sensitivity. A beta of 1.0 means the stock is modeled to move in line with the broader market, offering no defensive cushion.
Forensic Balance Sheet (5 / 20): Cited alongside an Altman Z-Score of 2.5, a Piotroski F-Score of 3/9, and a Debt/Equity ratio of 0.5. The F-Score of 3 out of 9 points to weak financial-health signals across the nine tests.

For a prospective investor, the practical implications are as follows. The upside case rests on a turnaround in operating economics, since current margins and returns are deeply negative. The valuation tradeoff is severe: with a market capitalization of $6.1M against reported net losses in the source, the equity is priced as a speculative option rather than a cash-generating business. Because every fundamental pillar scores at or below 7 of 20, the rating implies that the stock currently lacks offsetting strengths. The analytical takeaway is that this profile is consistent with high forensic risk, and the rating's verdict is to avoid rather than accumulate.

2. Business Model, Unit Margins & SEC Financial Trajectory

Intelligent Bio Solutions Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. It is classified under these sector and industry designations. —

The company reported operating and net losses in each listed period, with free cash flow negative in all three. Gross margin is 40.8%, while operating and net margins are both -60%, and ROIC is -35%. The Altman Z-Score is 2.5, and the Piotroski F-Score is 3 out of 9, . Cash declined from $2.2M in FY 2024 to $0.7M in FY 2025, and Debt/Equity is 0.5.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: The stock trades at a $6.1M market cap with revenue of $3.1M, leaving room for a sharp re-rating if operating losses narrow. With Fundamental Cash Engine at 7/20 (ROIC -35.0%, FCF yield —) and Institutional Whale Flow at 5/20, sustained execution supports upside toward the top of the $1.35 – $24.90 52-week range.
🐻 Primary Bear Case: Operating margin of -60%, FCF of -$9.9M against $0.7M in cash, and a Piotroski F-Score of 3/9 point to acute funding and forensic risk. Investors must weigh current valuation against -60.0% operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies cannot be mapped from the source. Sector-level context is limited to Health Care / Medical/Dental Instruments. Second-order bottlenecks cannot be identified from the provided data. —

Key Question #1: What specific products and customers generate the reported $3.1M in revenue, and what drives the operating loss?
Key Question #2: How much runway does the reported $0.7M in cash provide against FY 2025 free cash flow of -$9.9M?
Key Question #3: Why are EPS and forward valuation metrics unavailable, and what share count underlies the $6.1M market cap?

INBS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Intelligent Bio Solutions Inc. (INBS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to INBS Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 19h ago

Intelligent Bio Solutions Inc. Estimates – NASDAQ:INBS

TradingView report covering Intelligent Bio Solutions Inc. (INBS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 22h ago

Intelligent Bio Solutions Inc. (INBS) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Intelligent Bio Solutions Inc. (INBS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

CEO pay totaled $661K in fiscal 2026, Intelligent Bio Solutions (INBS) annual report amendment shows.

Stock Titan report covering Intelligent Bio Solutions Inc. (INBS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

12 Health Care Stocks Moving In Monday's After-Market Session - Flyte Aviation (AMEX:VJET), Option Care H

Benzinga report covering Intelligent Bio Solutions Inc. (INBS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Intelligent Bio Solutions (INBS) Slips 3.83% to $1.76 as Shares Test Lower Support Zone - High Conviction Picks

https://www.siam.in/ report covering Intelligent Bio Solutions Inc. (INBS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Tenon Medical, Inc. (TNON) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Intelligent Bio Solutions Inc. (INBS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Top U.S. Stock Losers: Biggest Price Declines

TradingKey report covering Intelligent Bio Solutions Inc. (INBS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - SCWorx (NASDAQ:WORX), Integra Lifesciences

Benzinga report covering Intelligent Bio Solutions Inc. (INBS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

INBS Bull vs. Bear Conversation Board — What's Your Call at $1.66?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON INBS 🐻 33% BEARISH CONVICTION

SI SiliconVal_Bull Growth & Tech Investor 🐂 BULLISH 🎯 Target: $2.02 (+14.8%)

📌 Pinned Debate

The stock trades at a $6.1M market cap with revenue of $3.1M, leaving room for a sharp re-rating if operating losses narrow.

The stock trades at a $6.1M market cap with revenue of $3.1M, leaving room for a sharp re-rating if operating losses narrow.. When you look under the hood at INBS, Fundamental Cash Engine is 7/20 with 40.8% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (5/20) has been quietly accumulating below $24.90. My 12M target is $2.02.

EarningsSniper 🐂 BULL

Both sides have a point here — INBS's 5/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

CR CreditSpread_Watch Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $1.36 (-22.7%)

Spot @ $1.76

Operating margin of -60%, FCF of -$9.9M against $0.7M in cash, and a Piotroski F-Score of 3/9 point to acute funding and forensic risk.

Operating margin of -60%, FCF of -$9.9M against $0.7M in cash, and a Piotroski F-Score of 3/9 point to acute funding and forensic risk.. Look at the math on INBS: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Medical/Dental Instruments demand softens. I'd wait for a retest of $1.55 before getting long.